news
A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. REUTERS/Julie Steenhuysen

Cleary Gottlieb Steen & Hamilton has advised Japanese pharmaceutical giant Takeda on its planned acquisition of U.S.-based Nimbus Therapeutics' experimental psoriasis drug, with Goodwin Procter acting for the seller.

The deal value is expected to be up to $6 billion, reported Reuters. It added that the drug, codenamed "NDI-034858", has shown statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year.

The Goodwin team was led by partners Bill Collins, Sarah Solomon and Yasin Akbari in Boston, and Erini Svokos in New York.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Cleary, A&G advise Japan’s Mitsui on $360 mln Ecuador shrimp deal

by Sarah Wong |

U.S. law firm Cleary Gottlieb Steen & Hamilton, Singapore’s Allen & Gledhill and two Ecuadorian firms have advised Japanese trading house Mitsui & Co on its $360 million investment in an Ecuadoran shrimp farming company.

Deals

Cleary, Freshies lead on China shoemaker’s planned $1 bln HK IPO

by Rowena Muñiz |

Cleary Gottlieb Steen & Hamilton and JunHe are advising Chinese footwear and apparel maker Belle Fashion Group on its planned Hong Kong IPO that is set to raise between $500 million and $1 billion. Freshfields Bruckhaus Deringer and Haiwen & Partners are representing the joint sponsors.

Deals

Cleary, Paul Hastings, Kim & Chang lead on Korea’s biggest IPO this year

by Nimitt Dixit |

U.S. law firms Cleary Gottlieb Steen & Hamilton and Paul Hastings, and South Korean law firm Kim & Chang have guided Doosan Robotics’ $317 million initial public offering on the Seoul Stock Exchange, the largest IPO in Korea this year.